Evidence map›Paper›PMID 24638003›Full record

Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2014

Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial.

Christopher L Corless, Karla V Ballman, Cristina R Antonescu, Violetta Kolesnikova, Robert G Maki, Peter W T Pisters, Martin E Blackstein, Charles D Blanke, George D Demetri, Michael C Heinrich and 5 more

Erratum issuedOpen access · bronzeAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 145 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
145citing papers in PubMed, 3 pooled it
23.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

145 citing papers in PubMed, 3 syntheses or guidelines pooled it, 314 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. KIT and PDGFRA Mutations and Survival of Gastrointestinal Stromal Tumor Patients Treated with Adjuvant Imatinib in a Randomized Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023
    Trial
  5. Trial
  6. Trial
  7. Trial
  8. Review
  9. Article
  10. Article
  11. Article
  12. Observational
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

85 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

  • Erratum issued
5 · Who and what money

Authors and funding

15 authors at 1 institution in 1 country.

Christopher L CorlessChristopher L. Corless, Violetta Kolesnikova, Charles D. Blanke, Michael C. Heinrich, Oregon Health and Science University, Portland, OR; Karla V. Ballman, Mayo Clinic, Rochester, MN; Cristina R. Antonescu and Ronald P. DeMatteo, Memorial Sloan-Kettering Cancer Center; Robert G. Maki, Mt Sinai School of Medicine, New York, NY; Peter W.T. Pisters and Shreyaskumar Patel, University of Texas MD Anderson Cancer Center, Houston, TX; Martin E. Blackstein, Mount Sinai Hospital, Toronto, Ontario, Canada; George D. Demetri, Dana-Farber Cancer Institute, Boston, MA; Margaret von Mehren, Fox Chase Cancer Institute, Philadelphia, PA; Martin D. McCarter, University of Colorado School of Medicine, Aurora, CO; and Kouros Owzar, Duke University School of Medicine, Durham, NC. corlessc@ohsu.edu.
Karla V BallmanChristopher L. Corless, Violetta Kolesnikova, Charles D. Blanke, Michael C. Heinrich, Oregon Health and Science University, Portland, OR; Karla V. Ballman, Mayo Clinic, Rochester, MN; Cristina R. Antonescu and Ronald P. DeMatteo, Memorial Sloan-Kettering Cancer Center; Robert G. Maki, Mt Sinai School of Medicine, New York, NY; Peter W.T. Pisters and Shreyaskumar Patel, University of Texas MD Anderson Cancer Center, Houston, TX; Martin E. Blackstein, Mount Sinai Hospital, Toronto, Ontario, Canada; George D. Demetri, Dana-Farber Cancer Institute, Boston, MA; Margaret von Mehren, Fox Chase Cancer Institute, Philadelphia, PA; Martin D. McCarter, University of Colorado School of Medicine, Aurora, CO; and Kouros Owzar, Duke University School of Medicine, Durham, NC.
Cristina R AntonescuChristopher L. Corless, Violetta Kolesnikova, Charles D. Blanke, Michael C. Heinrich, Oregon Health and Science University, Portland, OR; Karla V. Ballman, Mayo Clinic, Rochester, MN; Cristina R. Antonescu and Ronald P. DeMatteo, Memorial Sloan-Kettering Cancer Center; Robert G. Maki, Mt Sinai School of Medicine, New York, NY; Peter W.T. Pisters and Shreyaskumar Patel, University of Texas MD Anderson Cancer Center, Houston, TX; Martin E. Blackstein, Mount Sinai Hospital, Toronto, Ontario, Canada; George D. Demetri, Dana-Farber Cancer Institute, Boston, MA; Margaret von Mehren, Fox Chase Cancer Institute, Philadelphia, PA; Martin D. McCarter, University of Colorado School of Medicine, Aurora, CO; and Kouros Owzar, Duke University School of Medicine, Durham, NC.
Violetta KolesnikovaChristopher L. Corless, Violetta Kolesnikova, Charles D. Blanke, Michael C. Heinrich, Oregon Health and Science University, Portland, OR; Karla V. Ballman, Mayo Clinic, Rochester, MN; Cristina R. Antonescu and Ronald P. DeMatteo, Memorial Sloan-Kettering Cancer Center; Robert G. Maki, Mt Sinai School of Medicine, New York, NY; Peter W.T. Pisters and Shreyaskumar Patel, University of Texas MD Anderson Cancer Center, Houston, TX; Martin E. Blackstein, Mount Sinai Hospital, Toronto, Ontario, Canada; George D. Demetri, Dana-Farber Cancer Institute, Boston, MA; Margaret von Mehren, Fox Chase Cancer Institute, Philadelphia, PA; Martin D. McCarter, University of Colorado School of Medicine, Aurora, CO; and Kouros Owzar, Duke University School of Medicine, Durham, NC.
Robert G MakiChristopher L. Corless, Violetta Kolesnikova, Charles D. Blanke, Michael C. Heinrich, Oregon Health and Science University, Portland, OR; Karla V. Ballman, Mayo Clinic, Rochester, MN; Cristina R. Antonescu and Ronald P. DeMatteo, Memorial Sloan-Kettering Cancer Center; Robert G. Maki, Mt Sinai School of Medicine, New York, NY; Peter W.T. Pisters and Shreyaskumar Patel, University of Texas MD Anderson Cancer Center, Houston, TX; Martin E. Blackstein, Mount Sinai Hospital, Toronto, Ontario, Canada; George D. Demetri, Dana-Farber Cancer Institute, Boston, MA; Margaret von Mehren, Fox Chase Cancer Institute, Philadelphia, PA; Martin D. McCarter, University of Colorado School of Medicine, Aurora, CO; and Kouros Owzar, Duke University School of Medicine, Durham, NC.
Peter W T PistersChristopher L. Corless, Violetta Kolesnikova, Charles D. Blanke, Michael C. Heinrich, Oregon Health and Science University, Portland, OR; Karla V. Ballman, Mayo Clinic, Rochester, MN; Cristina R. Antonescu and Ronald P. DeMatteo, Memorial Sloan-Kettering Cancer Center; Robert G. Maki, Mt Sinai School of Medicine, New York, NY; Peter W.T. Pisters and Shreyaskumar Patel, University of Texas MD Anderson Cancer Center, Houston, TX; Martin E. Blackstein, Mount Sinai Hospital, Toronto, Ontario, Canada; George D. Demetri, Dana-Farber Cancer Institute, Boston, MA; Margaret von Mehren, Fox Chase Cancer Institute, Philadelphia, PA; Martin D. McCarter, University of Colorado School of Medicine, Aurora, CO; and Kouros Owzar, Duke University School of Medicine, Durham, NC.
Martin E BlacksteinChristopher L. Corless, Violetta Kolesnikova, Charles D. Blanke, Michael C. Heinrich, Oregon Health and Science University, Portland, OR; Karla V. Ballman, Mayo Clinic, Rochester, MN; Cristina R. Antonescu and Ronald P. DeMatteo, Memorial Sloan-Kettering Cancer Center; Robert G. Maki, Mt Sinai School of Medicine, New York, NY; Peter W.T. Pisters and Shreyaskumar Patel, University of Texas MD Anderson Cancer Center, Houston, TX; Martin E. Blackstein, Mount Sinai Hospital, Toronto, Ontario, Canada; George D. Demetri, Dana-Farber Cancer Institute, Boston, MA; Margaret von Mehren, Fox Chase Cancer Institute, Philadelphia, PA; Martin D. McCarter, University of Colorado School of Medicine, Aurora, CO; and Kouros Owzar, Duke University School of Medicine, Durham, NC.
Charles D BlankeChristopher L. Corless, Violetta Kolesnikova, Charles D. Blanke, Michael C. Heinrich, Oregon Health and Science University, Portland, OR; Karla V. Ballman, Mayo Clinic, Rochester, MN; Cristina R. Antonescu and Ronald P. DeMatteo, Memorial Sloan-Kettering Cancer Center; Robert G. Maki, Mt Sinai School of Medicine, New York, NY; Peter W.T. Pisters and Shreyaskumar Patel, University of Texas MD Anderson Cancer Center, Houston, TX; Martin E. Blackstein, Mount Sinai Hospital, Toronto, Ontario, Canada; George D. Demetri, Dana-Farber Cancer Institute, Boston, MA; Margaret von Mehren, Fox Chase Cancer Institute, Philadelphia, PA; Martin D. McCarter, University of Colorado School of Medicine, Aurora, CO; and Kouros Owzar, Duke University School of Medicine, Durham, NC.
George D DemetriChristopher L. Corless, Violetta Kolesnikova, Charles D. Blanke, Michael C. Heinrich, Oregon Health and Science University, Portland, OR; Karla V. Ballman, Mayo Clinic, Rochester, MN; Cristina R. Antonescu and Ronald P. DeMatteo, Memorial Sloan-Kettering Cancer Center; Robert G. Maki, Mt Sinai School of Medicine, New York, NY; Peter W.T. Pisters and Shreyaskumar Patel, University of Texas MD Anderson Cancer Center, Houston, TX; Martin E. Blackstein, Mount Sinai Hospital, Toronto, Ontario, Canada; George D. Demetri, Dana-Farber Cancer Institute, Boston, MA; Margaret von Mehren, Fox Chase Cancer Institute, Philadelphia, PA; Martin D. McCarter, University of Colorado School of Medicine, Aurora, CO; and Kouros Owzar, Duke University School of Medicine, Durham, NC.
Michael C HeinrichChristopher L. Corless, Violetta Kolesnikova, Charles D. Blanke, Michael C. Heinrich, Oregon Health and Science University, Portland, OR; Karla V. Ballman, Mayo Clinic, Rochester, MN; Cristina R. Antonescu and Ronald P. DeMatteo, Memorial Sloan-Kettering Cancer Center; Robert G. Maki, Mt Sinai School of Medicine, New York, NY; Peter W.T. Pisters and Shreyaskumar Patel, University of Texas MD Anderson Cancer Center, Houston, TX; Martin E. Blackstein, Mount Sinai Hospital, Toronto, Ontario, Canada; George D. Demetri, Dana-Farber Cancer Institute, Boston, MA; Margaret von Mehren, Fox Chase Cancer Institute, Philadelphia, PA; Martin D. McCarter, University of Colorado School of Medicine, Aurora, CO; and Kouros Owzar, Duke University School of Medicine, Durham, NC.
Margaret von MehrenChristopher L. Corless, Violetta Kolesnikova, Charles D. Blanke, Michael C. Heinrich, Oregon Health and Science University, Portland, OR; Karla V. Ballman, Mayo Clinic, Rochester, MN; Cristina R. Antonescu and Ronald P. DeMatteo, Memorial Sloan-Kettering Cancer Center; Robert G. Maki, Mt Sinai School of Medicine, New York, NY; Peter W.T. Pisters and Shreyaskumar Patel, University of Texas MD Anderson Cancer Center, Houston, TX; Martin E. Blackstein, Mount Sinai Hospital, Toronto, Ontario, Canada; George D. Demetri, Dana-Farber Cancer Institute, Boston, MA; Margaret von Mehren, Fox Chase Cancer Institute, Philadelphia, PA; Martin D. McCarter, University of Colorado School of Medicine, Aurora, CO; and Kouros Owzar, Duke University School of Medicine, Durham, NC.
Shreyaskumar PatelChristopher L. Corless, Violetta Kolesnikova, Charles D. Blanke, Michael C. Heinrich, Oregon Health and Science University, Portland, OR; Karla V. Ballman, Mayo Clinic, Rochester, MN; Cristina R. Antonescu and Ronald P. DeMatteo, Memorial Sloan-Kettering Cancer Center; Robert G. Maki, Mt Sinai School of Medicine, New York, NY; Peter W.T. Pisters and Shreyaskumar Patel, University of Texas MD Anderson Cancer Center, Houston, TX; Martin E. Blackstein, Mount Sinai Hospital, Toronto, Ontario, Canada; George D. Demetri, Dana-Farber Cancer Institute, Boston, MA; Margaret von Mehren, Fox Chase Cancer Institute, Philadelphia, PA; Martin D. McCarter, University of Colorado School of Medicine, Aurora, CO; and Kouros Owzar, Duke University School of Medicine, Durham, NC.
Martin D McCarterChristopher L. Corless, Violetta Kolesnikova, Charles D. Blanke, Michael C. Heinrich, Oregon Health and Science University, Portland, OR; Karla V. Ballman, Mayo Clinic, Rochester, MN; Cristina R. Antonescu and Ronald P. DeMatteo, Memorial Sloan-Kettering Cancer Center; Robert G. Maki, Mt Sinai School of Medicine, New York, NY; Peter W.T. Pisters and Shreyaskumar Patel, University of Texas MD Anderson Cancer Center, Houston, TX; Martin E. Blackstein, Mount Sinai Hospital, Toronto, Ontario, Canada; George D. Demetri, Dana-Farber Cancer Institute, Boston, MA; Margaret von Mehren, Fox Chase Cancer Institute, Philadelphia, PA; Martin D. McCarter, University of Colorado School of Medicine, Aurora, CO; and Kouros Owzar, Duke University School of Medicine, Durham, NC.
Kouros OwzarChristopher L. Corless, Violetta Kolesnikova, Charles D. Blanke, Michael C. Heinrich, Oregon Health and Science University, Portland, OR; Karla V. Ballman, Mayo Clinic, Rochester, MN; Cristina R. Antonescu and Ronald P. DeMatteo, Memorial Sloan-Kettering Cancer Center; Robert G. Maki, Mt Sinai School of Medicine, New York, NY; Peter W.T. Pisters and Shreyaskumar Patel, University of Texas MD Anderson Cancer Center, Houston, TX; Martin E. Blackstein, Mount Sinai Hospital, Toronto, Ontario, Canada; George D. Demetri, Dana-Farber Cancer Institute, Boston, MA; Margaret von Mehren, Fox Chase Cancer Institute, Philadelphia, PA; Martin D. McCarter, University of Colorado School of Medicine, Aurora, CO; and Kouros Owzar, Duke University School of Medicine, Durham, NC.
Ronald P DeMatteoChristopher L. Corless, Violetta Kolesnikova, Charles D. Blanke, Michael C. Heinrich, Oregon Health and Science University, Portland, OR; Karla V. Ballman, Mayo Clinic, Rochester, MN; Cristina R. Antonescu and Ronald P. DeMatteo, Memorial Sloan-Kettering Cancer Center; Robert G. Maki, Mt Sinai School of Medicine, New York, NY; Peter W.T. Pisters and Shreyaskumar Patel, University of Texas MD Anderson Cancer Center, Houston, TX; Martin E. Blackstein, Mount Sinai Hospital, Toronto, Ontario, Canada; George D. Demetri, Dana-Farber Cancer Institute, Boston, MA; Margaret von Mehren, Fox Chase Cancer Institute, Philadelphia, PA; Martin D. McCarter, University of Colorado School of Medicine, Aurora, CO; and Kouros Owzar, Duke University School of Medicine, Durham, NC.
Memorial Sloan Kettering Cancer Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Women's Cancer Research ProgramP30CA014236 · NCI · DUKE UNIVERSITY · PI DONNA NIEDZWIECKI · 1985 to 2026
$174.8M
CANCER AND LEUKEMIA GROUP B MINORITY SATELLITE SUPPLEMENU10CA031946 · NCI · UNIVERSITY OF CHICAGO · PI BERTAGNOLLI, MONICA M · 1985 to 2013
$158.4M
SWOG Network Group Operations Center of the NCTNU10CA180888 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI PRIMO N. LARA · 2014 to 2026
$152.1M
University of Colorado Cancer Center Support Grant - Lung Cancer Patient-Derived Xenografts with Autologous Human Immune SystemsP30CA046934 · NCI · UNIVERSITY OF COLORADO DENVER · PI James V Degregori · 1988 to 2026
$117.0M
Statistics CoreU10CA180882 · NCI · MAYO CLINIC ROCHESTER · PI Sumithra Jay Mandrekar · 2014 to 2026
$115.0M
CANCER &LEUKEMIA GROUP B STATISTICAL CENTERU10CA033601 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI SARGENT, DANIEL J. · 1985 to 2013
$69.4M
AMERICAN COLLEGE OF SURGEONS ONCOLOGY TRIALS GROUPU10CA076001 · NCI · DUKE UNIVERSITY · PI BERTAGNOLLI, MONICA M · 1998 to 2013
$62.1M
Tissue and Pathology ResourcesP50CA127003 · NCI · DANA-FARBER CANCER INST · PI EL-BARDEESY, NABEEL, SELLERS, WILLIAM R · 2007 to 2023
$33.2M
SPORE in Soft Tissue SarcomaP50CA140146 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SPRIGGS, DAVID R · 2010 to 2014
$11.1M
Molecular Mechanisms in Gastrointestinal Stromal TumorR01CA102613 · NCI · UNIVERSITY OF PENNSYLVANIA · PI Ronald P. Dematteo · 2004 to 2026
$9.2M
NCI NIH HHS CA033601NCI NIH HHS CA076001NCI NIH HHS CA102613NCI NIH HHS CA106588NCI NIH HHS CA150381NCI NIH HHS CA94503NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA014236NCI NIH HHS P30 CA016672NCI NIH HHS P30 CA046934NCI NIH HHS P50 CA127003NCI NIH HHS P50 CA140146NCI NIH HHS R01 CA102613NCI NIH HHS R01 CA106588NCI NIH HHS R21 CA150381NCI NIH HHS U10 CA031946NCI NIH HHS U10 CA033601NCI NIH HHS U10 CA076001NCI NIH HHS U10 CA180882NCI NIH HHS U10 CA180888
6 · The paper itself

Abstract

purposeThe ACOSOG (American College of Surgeons Oncology Group) Z9001 (Alliance) study, a randomized, placebo-controlled trial, demonstrated that 1 year of adjuvant imatinib prolonged recurrence-free survival (RFS) after resection of primary GI stromal tumor (GIST). We sought to determine the pathologic and molecular factors associated with patient outcome. PATIENTS AND

methodsThere were 328 patients assigned to the placebo arm and 317 to the imatinib arm. Median patient follow-up was 74 months. There were 645 tumor specimens available for mitotic rate or mutation analysis.

resultsRFS remained superior in the imatinib arm (hazard ratio, 0.6; 95% CI, 0.43 to 0.75; Cox model-adjusted P < .001). On multivariable analysis of patients in the placebo arm, large tumor size, small bowel location, and high mitotic rate were associated with lower RFS, whereas tumor genotype was not significantly associated with RFS. Multivariable analysis of patients in the imatinib arm yielded similar findings. When comparing the two arms, imatinib therapy was associated with higher RFS in patients with a KIT exon 11 deletion of any type, but not a KIT exon 11 insertion or point mutation, KIT exon 9 mutation, PDGFRA mutation, or wild-type tumor, although some of these patient groups were small. Adjuvant imatinib did not seem to alter overall survival.

conclusionOur findings show that tumor size, location, and mitotic rate, but not tumor genotype, are associated with the natural history of GIST. Patients with KIT exon 11 deletions assigned to 1 year of adjuvant imatinib had a longer RFS.

Indexed as

MutationAdolescentAdultAgedAged, 80 and overAntineoplastic AgentsBenzamidesChemotherapy, AdjuvantChi-Square DistributionDisease-Free SurvivalDNA Mutational AnalysisDouble-Blind MethodExonsFemaleGastrointestinal Stromal TumorsGenetic Predisposition to DiseaseAntineoplastic AgentsBenzamidesImatinib MesylatePiperazinesProtein Kinase InhibitorsProto-Oncogene Proteins c-kitPyrimidinesReceptor, Platelet-Derived Growth Factor alpha

Identifiers

PMID24638003
PMCPMC4026579
OpenAlexW2153405820

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.